Test your drug on human tumor models.

are spent on animal trials in Germany alone every year.

Solution

CanChip cuts preclinical costs by replacing low-predictive models with human-relevant data from day one.

of drugs that succeed in animal testing fail in humans.

Solution

Our tumor-on-chip models reproduce clinically validated drug responses — so your go/no-go decisions are based on human biology, not animal proxies.

is the average time for drug approval.

Solution

Human-relevant data earlier in the pipeline means faster iteration, fewer late-stage failures, and shorter timelines to market.